| Literature DB >> 30343587 |
Jinsoo Min1, Yoon Mi Shin2, Won Jae Lee2, Tung Thanh Truong3, Eun Seok Kang2, Jin Young An2,4, Kang Hyeon Choe2,4, Ki Man Lee2,4.
Abstract
OBJECTIVE: The growth of the older population is a great challenge for tuberculosis (TB) control in South Korea. This study was performed to investigate the clinical characteristics of and treatment outcomes among octogenarian patients with TB.Entities:
Keywords: Outcome; malignancy; mortality; octogenarian; sepsis; tuberculosis
Mesh:
Substances:
Year: 2018 PMID: 30343587 PMCID: PMC6384473 DOI: 10.1177/0300060518800597
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.Incidence rate of tuberculosis and number of tuberculosis-related deaths in South Korea (data from the annual report on the notified tuberculosis patients in Korea, 2016).
Demographic and clinical characteristics of 109 octogenarian patients with TB.
|
| |
| Age, years | 83.8 ± 3.4 |
| Male | 55 (50.5) |
| Body mass index, kg/m2 | 21.2 ± 3.5 |
| History of previous TB | 25 (22.9) |
| Current smoker | 35 (32.1) |
| Comorbidities | |
| Hypertension | 62 (56.9) |
| Diabetes mellitus | 27 (24.8) |
| Solid malignancy | 17 (15.6) |
| Chronic obstructive pulmonary disease | 14 (12.8) |
| Chronic kidney disease with dialysis | 1 (0.9) |
| Human immunodeficiency virus infection | 1 (0.9) |
| Initial symptoms | |
| Cough | 59 (54.1) |
| Sputum | 54 (49.5) |
| Fever | 28 (25.7) |
| Dyspnea | 57 (52.3) |
| Interval from symptom onset to first hospital visit, days | 7 [1–14] |
| Interval from first hospital visit to anti-TB treatment, days | 8 [4–16] |
| Anti-TB treatment regimen | |
| HREZ | 82 (75.2) |
| HRE | 10 (9.2) |
| HR | 8 (7.3) |
| Other combination regimen including second-line drugs | 6 (5.5) |
| No treatment | 3 (2.8) |
| Treatment outcome | |
| Cured | 9 (8.3) |
| Complete | 71 (65.1) |
| Death | 21 (19.3) |
| Loss to follow-up | 8 (7.3) |
Data are presented as mean ± standard deviation, n (%), or median (interquartile range).
TB, tuberculosis; HREZ, combination regimen of isoniazid, rifampicin, ethambutol, and pyrazinamide; HRE, combination regimen of isoniazid, rifampicin, and ethambutol; HR, combination regimen of isoniazid and rifampicin.
Microbiological, radiological, and pathological findings of 109 octogenarian patients with TB.
| Characteristics | All(n = 109) | Pulmonary TB (n = 84) | Extrapulmonary TB (n = 25) | p-value |
|---|---|---|---|---|
| Microbiological findings | ||||
| Positive AFB smear | 18 (16.5) | 18 (21.4) | 0 (0.0) | 0.011 |
| Positive AFB culture | 46 (42.2) | 46 (54.8) | 0 (0.0) | 0.000 |
| Positive TB-PCR assay | 20 (18.3) | 20 (23.8) | 0 (0.0) | 0.003 |
| At least one positive mycobacterial test result | 56 (51.4) | 56 (66.7) | 0 (0.0) | 0.000 |
| Radiologic findings | ||||
| Active lesions suggestive of TB | 35 (32.1) | 33 (39.3) | 2 (8.0) | 0.013 |
| Active lesions suggestive of conditions other than TB§ | 57 (52.3) | 39 (46.4) | 18 (72.0) | |
| Inactive lesions¶ | 17 (15.6) | 12 (14.3) | 5 (20.0) | |
| Radiologically confirmed TB cases | 57 (52.3) | 51 (46.8) | 6 (24.0) | 0.001 |
| Pathological findings consistent with TB | 21 (19.3) | 15 (17.8) | 6 (24.0) | 0.494 |
Data are presented as n (%).
SD, standard deviation; TB, tuberculosis; AFB, acid-fast bacilli; PCR, polymerase chain reaction.
§Lesions suggestive of infection, malignant mass, lung nodule, or pleural effusion.
¶Lesions such as fibrotic changes of lung parenchyma or atelectasis.
Causes of death among 21 octogenarian patients with TB.
| Cause of death | |
| TB-related death (n = 2) | |
| Respiratory failure | 2 (9.5) |
| Non-TB-related death (n = 15) | |
| Malignancy | 5 (23.8) |
| Sepsis or septic shock | 5 (23.8) |
| Pneumonia with respiratory failure | 3 (14.3) |
| Acute exacerbation of chronic respiratory disease | 1 (4.8) |
| Heart failure | 1 (4.8) |
| Unknown cause of death (n=4) |
Data are presented as n (%).
TB, tuberculosis.
Comparison of risk factors for mortality among 109 patients with TB.
| Variables | Survival(n = 88) | Death(n = 21) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |||
| Age, years | 83.8 ± 3.4 | 84.0 ± 3.6 | 1.02 (0.89–1.17) | 0.815 | 1.07 (092–1.25) | 0.389 |
| Male | 40 (45.5) | 15 (71.4) | 3.00 (1.07–8.45) | 0.038 | 2.15 (0.58–7.99) | 0.254 |
| Body mass index, kg/m2 | 21.3 ± 3.4 | 20.5 ± 4.0 | 0.92 (0.80–1.07) | 0.281 | ||
| History of previous TB | 17 (19.3) | 8 (38.1) | 2.57 (0.92–7.18) | 0.072 | 2.96 (0.90–9.75) | 0.074 |
| Current smoker | 26 (29.5) | 9 (42.9) | 1.64 (0.62–4.39) | 0.320 | 1.35 (0.38–4.74) | 0.643 |
| Diabetes mellitus | 21 (23.9) | 6 (28.6) | 1.28 (0.44–3.71) | 0.654 | ||
| Solid malignancy | 9 (10.2) | 8 (38.1) | 5.40 (1.77–16.53) | 0.003 | 6.72 (1.89–23.90) | 0.003 |
| Chronic obstructive pulmonary disease | 11 (12.5) | 3 (14.3) | 1.18 (0.30–4.62) | 0.826 | ||
| Fever | 23 (26.1) | 5 (23.8) | 0.88 (0.29–2.68) | 0.827 | ||
| Dyspnea | 46 (69.7) | 11 (52.4) | 1.00 (0.39–2.61) | 0.993 | ||
| Positive AFB smear test result | 14 (15.9) | 4 (19.0) | 1.24 (0.36–4.26) | 0.728 | ||
| Positive AFB culture test result | 40 (45.5) | 6 (28.6) | 0.48 (0.17–1.35) | 0.165 | ||
| Radiologic findings | ||||||
| Inactive lesions | 16 (18.2) | 1 (4.8) | ||||
| Active lesions suspicious of TB | 32 (36.4) | 4 (19.0) | 2.07 (0.21–20.04) | 0.532 | ||
| Active lesions other than TB | 41 (46.6) | 16 (76.2) | 6.24 (0.76–51.05) | 0.088 | ||
Data in survival and death groups are presented as mean ± standard deviation or n (%).
OR, odds ratio; CI, confidence interval; TB, tuberculosis; AFB, acid-fast bacilli.
Cancer treatment and anti-TB treatment of 17 patients with TB and malignancy.
| Age/Sex | TB site | Cancer site | Interval between cancer diagnosis and ATT | Treatment related to cancer before diagnosis of TB | Outcome |
|---|---|---|---|---|---|
| 82/M | Lung | Lung | 3 mo | Only supportive care | Death |
| 82/M | Lung | Lung | 35 mo | Cancer progression after chemotherapy | Death |
| 81/M | Lung | Lung | 1 mo | Hospice care without chemotherapy | Death |
| 82/M | Lung | Lung | During ATT | Simultaneous diagnosis of TB and cancer | Death |
| 84/F | Lung | Colon | 5 mo | Cancer progression after chemotherapy | Death |
| 85/F | Lung | Colon | 13 mo | Conservative care after surgical resection | Death |
| 85/M | Lung | Prostate | 48 mo | Palliative therapy after chemotherapy | Death |
| 80/M | Lung | Skin | 2 mo | Surgery followed by radiotherapy | Death |
| 81/M | Lung | Lung | During ATT | Only supportive care | Complete |
| 81/M | Lung | Lung | During ATT | Surgical resection | Complete |
| 82/F | Lung and bone | Stomach | 22 mo | Endoscopic resection | Complete |
| 84/F | CNS | Stomach | 8 mo | Surgical resection | Complete |
| 80/F | Lung | Rectum | During ATT | Surgical resection | Complete |
| 91/M | Lung | Stomach | 36 mo | Surgical resection | Cure |
| 82/M | Lung | Stomach | 60 mo | Surgical resection | Cure |
| 83/M | Lung | Liver | 40 mo | Transarterial chemoembolization | F/U loss |
M, male; F, female; mo, months; CNS, central nervous system; ATT, anti-tuberculosis treatment; TB, tuberculosis; F/U, follow-up.